| 产品描述: | IDO1-IN-19 (Compound 17) is an orally active IDO1 inhibitor with an IC50 of CYP2C9 of 8.64 μM. IDO1-IN-19 also acts funciton on cardiac channels, with IC50s of 12 μM (IKr), 40 μM (INa), 8.3 μM (ICa), respectively. IDO1-IN-19 has the potential to study cancer diseases. |
| 靶点: |
IDO1;CYP2C9:8.64 μM (IC50); ICa:8.3 μM (IC50); IKr:12 μM (IC50) |
| 体外研究: |
IDO1-IN-19 (0.3-30 mg/kg; 口服; 单剂量) 可降低 hIDO1 转基因荷瘤小鼠的肿瘤中的 Kyn 水平 (Kyn 是 IDO 在体内催化 Trp 的代谢产物)。 |
| 保存条件: |
-80°C 6个月;-20°C 1个月 |
| 配置溶液浓度参考: |
|
1mg |
5mg |
10mg |
| 1 mM |
2.108 ml |
10.539 ml |
21.077 ml |
| 5 mM |
0.422 ml |
2.108 ml |
4.215 ml |
| 10 mM |
0.211 ml |
1.054 ml |
2.108 ml |
| 50 mM |
0.042 ml |
0.211 ml |
0.422 ml |
|
| 注意: |
部分产品我司仅能提供部分信息,我司不保证所提供信息的权威性,仅供客户参考交流研究之用。 |